Trial Profile
The effect of Memantine on negative symptoms in patients with chronic schizophrenia: a double blind and placebo controlled trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2013
Price :
$35
*
At a glance
- Drugs Memantine (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Therapeutic Use
- 19 Apr 2013 Status changed from active, no longer recruiting to completed.
- 05 Apr 2012 Planned end date (10 Sep 2011) added as reportrf by Iranian Registry of Clinical Trial.
- 14 Oct 2011 New trial record